EGFR and adenocarcinoma: In contrast to non-small cell lung cancer and adenocarcinoma harboring activating nucleotide mutations within the EGFR kinase domain, GBM overly activates EGFR by the increasing copy number and the substituted mutations occur in the extracellular domain (39) (Figure 4).